These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12442678)

  • 1. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A; Huang Z; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
    [No Abstract]   [Full Text] [Related]  

  • 2. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
    Wenzelburger R
    Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
    [No Abstract]   [Full Text] [Related]  

  • 5. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 6. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nondopaminergic mechanisms in levodopa-induced dyskinesia.
    Brotchie JM
    Mov Disord; 2005 Aug; 20(8):919-31. PubMed ID: 16007614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease.
    Deogaonkar M; Subramanian T
    Brain Res Brain Res Rev; 2005 Dec; 50(1):156-68. PubMed ID: 16026845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to modify levodopa treatment.
    Widner H
    Adv Neurol; 2003; 91():229-36. PubMed ID: 12442681
    [No Abstract]   [Full Text] [Related]  

  • 11. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 12. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Punding in Parkinson's disease.
    O'Sullivan SS; Evans AH; Lees AJ
    Pract Neurol; 2007 Nov; 7(6):397-9. PubMed ID: 18024780
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of later phases of Parkinson disease].
    Tison F
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F85-8. PubMed ID: 18680823
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M; Carlsson T; Kirik D; Björklund A
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 18. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.